$0.384
+0.063 (+16.36%)At close
XTNT News
XTNT Events
Xtant Medical Partners Exclusively with BioHorizons
Xtant Medical announced an exclusive partnership with BioHorizons, whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolifica through its commercial network. The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and Canada, expanding access to the advanced allograft technology for clinicians served by the BioHorizons commercial organization. The partnership reflects a long-term strategic relationship between the two companies, combining Xtant's regenerative medicine development and manufacturing capabilities with BioHorizons' established commercial reach and customer relationships. Both companies expect the collaboration to create a durable channel for expanding access to Prolifica and to serve as a foundation for continued collaboration between the organizations.
Revenue Guidance Increased Following Exclusive License Agreement with Dilon Technologies
Revenue guidance increase reflects the recently announced exclusive license agreement with Dilon Technologies and anticipated incremental revenue contribution from Dilon's HEMOBLAST Bellows.
Xtant Medical Reports Q1 Revenue of $20.9M
Reports Q1 revenue $20.9M vs. $32.9M last year. Sean Browne, President and CEO of Xtant Medical, stated, "The Q1 of 2026 and subsequent period were pivotal for Xtant. Proceeds from the Companion Spine transaction allowed us to strengthen our balance sheet while the HEMOBLAST Bellows distribution agreement announced in April expanded our addressable market into the multi-billion-dollar hemostatics category. We are particularly encouraged by the potential commercial synergies to be realized following the integration of Dilon's 21-person field sales force into our own organization, positioning us to drive topline growth and margin expansion this year and beyond. These developments, together with recent product launches, position us to best serve the needs of surgeons and patients alike with our comprehensive biologics product portfolio."
Xtant Medical Acquires Exclusive U.S. Distribution Rights for Dilon's Hemoblast Bellows
Xtant Medical Holdings and Dilon Technologies announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's Hemoblast Bellows for high-performance hemostasis following certain surgical procedures. Xtant plans to update its full-year 2026 financial guidance in light of the new distribution arrangement in connection with the release of its first quarter 2026 financial results.
Xtant Reports Q4 Revenue of $32.4M, Sees Positive Cash Flow in 2026
Reports Q4 revenue $32.4M vs. $ last year. CEO Sean Browne stated, "Our Q4 2025 caps a truly transformational year for Xtant, during which we meaningfully sharpened our focus on our core biologics business while driving the new product innovation for which we are known. Along the way, in 2025 we achieved profitability and cash flow generation, reflecting robust topline growth, targeted R&D investments, and prudent expense management...Those cash flows, along with the divestiture of certain non-core products and operations, provided Xtant with the capital to focus on internally developing our advanced biologics product lines, including new products released in 2025...Looking ahead to 2026, with the recent receipt of amounts previously outstanding under our note receivable from the Companion Spine transaction, we have increased our current cash position to over $22M while reducing our term loan balance to $11.2M. Given our significantly strengthened financial position, we do not see any need to raise additional outside capital to run our operations and we expect to be free cash flow positive in 2026. Moreover, this year we plan to lean into our strengths in biologics and invest in our commercial team to focus on profitably growing our core biologics business. With the substantial progress made in 2025, I am excited for this year and beyond".
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。